This shareholder presentation by NEMUS Bioscience provides an overview of the company's progress and plans. In the past year, NEMUS licensed drug candidates from the University of Mississippi, conducted preclinical research, established business operations, and raised $4.15 million. Looking ahead, the company plans to finalize a glaucoma drug formulation, complete preclinical studies for FDA approval, license additional candidates for MRSA and CBD, and raise further capital to advance development programs and uplist to a national stock exchange.

1. Shareholder Presentation
July 9, 2015
OTCQB: NMUS

2. Foreward Looking Statement
NEMUS Shareholder Presentation | 2Confidential Information
This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. All of the statements in this presentation, whether written or oral, that refer to expected or anticipated future
actions and results of NEMUS Bioscience, Inc. (NEMUS) are forward-looking statements. These forward-looking statements reflect the
beliefs and expectations of the management of NEMUS as of the date of this presentation. NEMUS cannot give any assurance that such
forward-looking statements will prove to be correct. The reader is cautioned not to place undue reliance on these forward-looking
statements.
The information provided in this presentation does not identify or include any risk or exposures, of NEMUS that would materially
adversely affect the performance or risk of the company. For a description of the risks and uncertainties related to the business of NEMUS,
see our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission on March 27,
2015 and our subsequent periodic reports filed with the Securities and Exchange Commission.
All information contained in this presentation is provided as of the date of the presentation and is subject to change without notice. Neither
NEMUS, nor any other person undertakes any obligation to update or revise publicly any of the forward-looking statements set out herein,
whether as a result of new information, future events or otherwise, except as required by law. This presentation does not convey an offer of
any type and is not intended to be, and should not be construed as, an offer to sell, or the solicitation of an offer to buy, any securities of
NEMUS.

3. Year in Review
NEMUS Shareholder Presentation | 3Confidential Information
Creating our Products:
• Licensed from the University of Mississippi the worldwide, exclusive, perpetual rights for UM5050
• Licensed exclusive rights for three formulations UM5050 (Ocular, Transmucosal and Rectal)
• Completed extensive IP work to support licensing decisions
• Conducted strategic asset management work to determine optimal direction
• Created the draft development path for glaucoma
• MRSA Research agreement signed and work initiated
• Identified potential way to achieve improved product profile for glaucoma candidate (Solid Lipid Nanoparticles; SLN)
• Vetted UOM and now know that the lead compound has multiple mechanisms of action
• CBD research agreement signed and significant progress made

4. Year in Review
NEMUS Shareholder Presentation | 4Confidential Information
Creating the Company:
• Hired a tremendous CMO and CFO
• Successfully completed reverse merger and moved from the OTCBB to OTCQB
• Added three world class independent board members to the NEMUS Board
• Established systems to operate in a fully compliant manner
• Successfully filed all necessary documents for all quarters and year end
• Enlisted the assistance of top name partners: Latham and Watkins, Mayer Hoffman McCann, Deloitte, the MZ
Group, Keelin Reeds, Atheln
• Became the first laboratory occupants in Insight Park, University of Mississippi
Creating the Financial Support to Accomplish our Goals:
• Raised $4.15M since inception
• Created plan to raise the necessary finances to execute development plans for glaucoma, MRSA and CBD
• Gained awareness in investment community about NEMUS

5. Plan for the Year Ahead
NEMUS Shareholder Presentation | 5Confidential Information
Expectations for Creating our Products:
• Finalize our glaucoma formulation
• Conduct all necessary preclinical work to be prepared for IND enabling studies/work in 2016
• Conduct necessary IP work for MRSA and CBD
• Sign both an MRSA and CBD license agreement with the UOM
• Determine optimal clinical targets for new programs
• Create development plans for both
• Meet with the FDA in pre-IND meeting
Expectations for Creating the Company:
• Expand our Scientific Advisory Board
• Select a Contract Manufacturing Organization (CMO) partner
• Partner with Contract Research Organization/consultancy to serve as our Development team
• Add selected key personnel to the staff
Expectations for Creating the Financial Support to Accomplish our Goals:
• Raise the capital necessary to achieve our goals
• Enlisting the assistance of investment banks to achieve our goals
• Prepare to and evaluate ability to meet appropriate criteria and qualify for uplisting to NYSE or NASDAQ
• Increase awareness in all facets of the investment community